All News

In this chapter, Dr. Owen reviews the diagnosis or cervical insufficiency; patient selection for history-indicated (prophylactic), physical examination-indicated (Emergent), and ultrasound-indicated (urgent) cerclage; placement and removal of cerclagel and adjunctive therapies.

The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Analysis by the United States Food and Drug Administration (FDA) of compounded 17α-hydroxyprogesterone caproate (17P) shows the samples meet the potency and total purity standards for Makena, the branded version of the drug. Testing was done on 16 samples of bulk 17P active pharmaceutical ingredients (API) in response to questions from K-V Pharmaceuticals, Makena’s sponsor, about potency and purity of the compounded product.

Scientists are testing a procedure that allows women with a genetic disorder conceive without passing the disease on to their children, and it involves using DNA from a "third parent." Is it ethical?

Estrogen-deficient women who have had a hysterectomy with or without ovarian preservation are more likely to have arterial stiffness than estrogen-deficient women who have not had a hysterectomy, according to results of a new study conducted at the University of Colorado School of Medicine in Denver.